Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.37 |
| ▸ | PDE9A | O76083 | 11/20 | 0.32 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22245149 | 0.81 | KDM4C (0.40) | KDM4CPDE9A | |
| SCHEMBL22119244 | 0.80 | KDM4C (0.38) | KDM4CPDE9AKDM4EALDH1A1 | |
| SCHEMBL29540293 | 0.80 | STK33 (0.43) | PDE9AKDM4EALDH1A1 | |
| SCHEMBL22245218 | 0.80 | STK33 (0.43) | PDE9AKDM4EALDH1A1 | |
| SCHEMBL22245142 | 0.79 | KDM4C (0.36) | KDM4CPDE9AKDM4EALDH1A1 | |
| SCHEMBL22119389 | 0.79 | SYK (0.36) | KDM4CPDE9A | |
| SCHEMBL22268012 | 0.79 | S1PR2 (0.43) | PDE9AS1PR2 | |
| SCHEMBL22119369 | 0.78 | PDE9A (0.38) | KDM4CPDE9A | |
| SCHEMBL26221035 | 0.78 | KDM4C (0.51) | KDM4CPDE9AKDM4EALDH1A1 | |
| SCHEMBL22119374 | 0.76 | PDE9A (0.38) | KDM4CPDE9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534470-B2 | DNA polymerase IIIC inhibitors and use thereof | Acurx Pharmaceuticals, Inc. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2023-08-10 | — | — | US | disclosed |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2023-08-10 | — | — | US | disclosed |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2023-08-10 | — | — | US | disclosed |
| US-20220112195-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | ACURX PHARMACEUTICALS LLC (US) | 2022-04-14 | — | — | US | disclosed |
| US-11001592-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-11001592-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-10836772-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836772-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200308179-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2020-10-01 | — | — | US | disclosed |
| US-20200308179-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2020-10-01 | — | — | US | disclosed |
| US-20200308180-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2020-10-01 | — | — | US | disclosed |
| US-20200308180-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2020-10-01 | — | — | US | disclosed |
| US-10723741-B1 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-10723741-B1 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2020-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112195-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | KDM4C 817/4885PDE9A 2005/4885GPR142 4556/4885 |
| US-12534470-B2 | DNA polymerase IIIC inhibitors and use thereof | POLR1A, POLR2H, POLN | KDM4C 277/4885PDE9A 2788/4885GPR142 3273/4885 |
| US-20200308180-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | KDM4C 785/4885PDE9A 2025/4885GPR142 4505/4885 |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | KDM4C 817/4885PDE9A 2005/4885GPR142 4556/4885 |
| US-20200308179-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | KDM4C 785/4885PDE9A 2025/4885GPR142 4505/4885 |
| US-11001592-B2 | DNA polymerase IIIC inhibitors and use thereof | POLI, POLN, POLB | KDM4C 785/4885PDE9A 2025/4885GPR142 4505/4885 |
| US-10723741-B1 | DNA polymerase IIIC inhibitors and use thereof | POLI, POLN, POLB | KDM4C 817/4885PDE9A 2005/4885GPR142 4556/4885 |
| US-10836772-B2 | DNA polymerase IIIC inhibitors and use thereof | POLI, POLN, POLB | KDM4C 785/4885PDE9A 2025/4885GPR142 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.